Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 177-Lu Edotreotide
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Isotope Technologies Munich
Deal Size : $204.0 million
Deal Type : Financing
ITM Raises €188M to Enhance Radiopharmaceutical Pipeline and Strengthen Position
Details : The proceeds will be used to prepare commercial readiness for the potential market launch of the company’s phase III lead candidate, ITM-11 (177Lu-edotreotide) for the treatment of GEP-NETs.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
June 06, 2024
Lead Product(s) : 177-Lu Edotreotide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Isotope Technologies Munich
Deal Size : $204.0 million
Deal Type : Financing
Lead Product(s) : 177-Lu Edotreotide,Everolimus,Lysine
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Isotope Technologies Munich
Deal Size : $272.7 million
Deal Type : Financing
Details : The net financing will support the development of ITM’s broad Targeted Radionuclide Therapies oncology pipeline and enhance phase III clinical development for its lead pipeline candidate, ITM-11 (n.c.a. 177Lu-edotreotide) in gastroenteropancreatic neur...
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
May 06, 2023
Lead Product(s) : 177-Lu Edotreotide,Everolimus,Lysine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Isotope Technologies Munich
Deal Size : $272.7 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Recipient : Arbor Biotechnologies
Deal Size : $215.0 million
Deal Type : Series B Financing
Details : Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while continuing to invest in its novel discovery engine to develop the next generation of ge...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 11, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Recipient : Arbor Biotechnologies
Deal Size : $215.0 million
Deal Type : Series B Financing
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : BioNTech
Deal Size : $250.0 million
Deal Type : Funding
Temasek Leads a $250M Raise for BioNTech as First Covid-19 mRNA Vaccine Data Looms
Details : BioNTech is expected to post data from its Phase I/II trial virtually any day now, as analysts expect some hard numbers on immunogenicity and safety for BNT162 in the June/July time frame.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : $139.0 million
June 29, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : BioNTech
Deal Size : $250.0 million
Deal Type : Funding
Lead Product(s) : SQZ-PBMC-HPV,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : SQZ Biotechnologies
Deal Size : $65.0 million
Deal Type : Series D Financing
SQZ Biotech Snags $65M To Push Cancer Vaccine, Break Into Infectious Disease
Details : The money raised will support SQZ's pipeline, including an expansion into infectious diseases. In addition to the SQZ-PBMC-HPV, the company is developing another novel cell therapy in the cancer space, activating antigen carriers (SQZ AACs).
Product Name : SQZ-PBMC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 21, 2020
Lead Product(s) : SQZ-PBMC-HPV,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : SQZ Biotechnologies
Deal Size : $65.0 million
Deal Type : Series D Financing
Reset All
